RP1 Plus Nivolumab Generates Activity in Pretreated Cutaneous Melanoma
Source: Onc Nursing News, December 2022
A combination of vusolimogene oderparepvec and nivolumab elicited early clinical activity in patients with cutaneous melanoma whose disease did not response to anti-PD-1 therapy.
Patients with cutaneous melanoma whose disease did not response to anti–PD-1 therapy achieved encouraging initial responses with a combination of vusolimogene oderparepvec (RP1) and nivolumab (Opdivo) in the phase 2 IGNYTE trial (NCT03767348).
At a median follow-up of 9.96 months, the first 75 patients enrolled on the trial achieved an overall response rate (ORR) over 36%, including a complete response (CR) rate of 20% and a partial response rate of 16.0%.2 Furthermore, 17.3% of patients had stable disease, and 42.7% experienced progressive disease. The disease control rate (DCR) was 53.3%.